Medical Therapy of Peripheral Artery Disease
|
|
- Cecily Harris
- 6 years ago
- Views:
Transcription
1 Medical Therapy of Peripheral Artery Disease Alvaro Alonso, MD Assistant Professor of Medicine Associate Director, Interven4onal Cardiology Fellowship Program Tulane University Heart & Vascular Ins4tute Tulane University School of Medicine New Orleans, LA (USA)
2 Disclosures Grant/Research Support: Supported in part by the National Institute of General Medical Sciences of the National Institutes of Health under award number 1 U54 GM104940, which funds the Louisiana Clinical and Translational Science Center Principal Investigator: Odyssey Outcomes RCT (Sanofi-Regeneron; Alirocumab). Not-financial. Nothing to disclose regarding: Speaker s Bureau Honorarium Consultant Stockholder Medical/Scientific Boards
3 LE-PAD: More Prevalent and More Deadly Than Many Leading Diseases Fowkes FG. Lancet. 2013;382(9901): Adapted, Courtesy of: Subhash Banerjee, M.D U.S. Disease Prevalence (Millions) % 40% 30% 20% 10% 0% Five-Year Mortality Rate 39% 30% 28% 21% 14%
4 Natural History of Atherosclerotic LE-PAD For each of these PAD clinical syndromes Asymptomatic PAD 20%-50% Limb morbidity Claudication 10%-35% 5-year outcomes Atypical leg pain 40%-50% Cardiovascular M&M Stable claudication 70%-80% Worse claudication 10%-20% Critical limb ischemia 1%-2% Amputation (next slide) Nonfatal CV event (MI or stroke) 20% CV causes 75% Mortality 15%-30% Non-CV causes 25% Hirsch AT, et al. Circulation. 2006;113:e
5 Natural History of Atherosclerotic LE-PAD Cont d PAD Population Initial clinical presentation Asymptomatic PAD 20%-50% Progressive functional impairment Atypical leg pain 40%-50% 5-year outcomes Claudication 10%-35% Alive w/ 2 limbs 50% Critical limb ischemia 1%-2% 1-year outcomes Amputation 25% CV mortality 25% (previous slide) Hirsch AT, et al. Circulation. 2006;113:e
6 Major Goals of Treatment in LE-PAD Cardiovascular Limb outcomes á ability to walk á peak walking distance á quality-of-life (QoL) Prevention of progression to CLI and amputation morbidity and mortality outcomes â morbidity from nonfatal MI and stroke â cardiovascular mortality from fatal MI and stroke
7 Smoking cessation Antiplatelet therapy ASA Clopidogrel Essentials ASA + clopidogrel? Ticagrelor (ongoing EUCLID trial) Blood pressure control Glycemic control
8 Cilostazol and Walking Distance in Claudication Meters (mean) * P < 0.05 vs. placebo * * * * * * * * Weeks of Treatment * * * * * * * * * * * * Maximal Walking Distance Cilostazol 100 mg bid (n=140) Cilostazol 50 mg bid (n=139) Placebo (n=140) Pain-Free Walking Distance Beebe, et al. Arch Intern Med. 1999;159:
9 Effect of Cilostazol on Quality of Life Medical Outcome Scale SF-36 RCT, N = 1751 Physical Summary Score Placebo * P < 0.05 Cilostazol 100 mg bid * * * * Wk 4 Wk 8 Wk 16 Wk 20 Wk 24 Weeks of treatment * Regensteiner MG et al. J Am Geriatr Soc Dec;50(12):
10 Cilostazol Restenosis and Vascular events STOP-IC RCT, N= 200 Femoropopliteal PVI Freedom from death, major amputation, clinical TLR, limb ischemia requiring surgical intervention Cilostazol Non-cilostazol 49% Cilostazol 20% 12-mo angiographic restenosis Iida O et al. Circulation. 2013;127:
11 Cilostazol Improved outcomes after PVI for CLI Warner CJ, et al. J Vasc Surg 2014;59:
12 Statin use Vascular Events Heart Protection Study Heart Protection Study Collaborative Group. Lancet. 2002;360:7-22.
13 RCT, N= 354 Statins Pain Free Walking Time Mean change from baseline in Pain Free Walking Time (sec) Atorvastatin 10 mg Atorvastatin 80 mg Placebo Baseline Month 3 Month 6 Month 12 * *P=0.03 No change in ABI over 12 months. Mohler ER et al. Circulation. 2003;108:
14 Ramipril use Cardiovascular risk HOPE: Benefits in CV Risk Subgroups N Engl J Med. 2000;342:
15 ACEI (ramipril vs. others) Δ in mean walking distance (meters) Shahin Y, et al. Atherosclerosis 2013;231:
16
17
18 Intermittent Claudication: Supervised Exercise Therapy Warm-up Exercise Rest Exercise Rest Exercise Cool-down 3 5 supervised sessions/week minutes of exercise/session Treadmill or track walking to nearmaximal claudication pain 6 months Gardner AW, Poehlman ET. JAMA. 1995;274: Stewart KJ et al. N Eng J Med. 2002;347: Change in Treadmill Walking Distance (%) Meta-analysis of 21 Studies P < 0.05 Onset of Claudication Pain Exercise Training Control P < 0.05 Maximal Claudication Pain
19 CLEVER Combination therapy NIH-sponsored multicenter RCT, N = 111, aorto-iliac disease Randomized to OMT vs. OMT+Stent vs. OMT+Exercise, 6mo f/u 1 endpoint: Change in peak walking time 8 (p < 0.05 for all comparisons) OMT = Cilostazol 4 % Optimal medical therapy ( N = 22) Stent revascularization (N = 46) Exercise program ( N = 43) Quality of Life: with stenting, supervised exercise medical therapy Circulation 2012;125(1):130-9
20 CLEVER mean Peak Walking Time 18 month results J Am Coll Cardiol 2015;65:
21 CLEVER Baseline medication use Medication use, % OMT (n = 22) Exercise + OMT (n = 43) Stenting + OMT (n = 46) Aspirin P2Y12 inhibitor Statin No information on ACE inhibitor use No information on medication use at f/u p = NS for all groups CLEVER 6 month results. Circulation. 2012;125:
22 Revascularization Symptomatic patients Refractory to medical therapy; lifestyle limiting Depending on clinical presentation (ALI vs. CLI vs. Claudication) Medications Antiplatelets Cilostazol Ramipril Statin Exercise Smoking cessation Surgical Control of other CV risk factors as surgical bridge or post-surgical salvage Revascularization Endovascular Endovascular Revascularization
23 Conclusions Medical therapy goals Improve cardiovascular outcomes Symptom management Contemporary therapies inter-related Med Rx improves ambulation distance quality of life limb outcomes cardiovascular outcomes
24 cardiacandvascular.org Thank you
25 Medical Therapy of Peripheral Artery Disease Alvaro Alonso, MD Assistant Professor of Medicine Associate Director, Interven4onal Cardiology Fellowship Program Tulane University Heart & Vascular Ins4tute Tulane University School of Medicine New Orleans, LA (USA)
26
27
28 Objective Acquire/increase/affirm your knowledge about the contemporary medical management of patients with lower extremity peripheral arterial disease
29 Global burden of LE-PAD 220 million patients worldwide ~ 12 million patients in the United States Fowkes FG. Lancet. 2013;382(9901):
30 Association Between ABI and All Cause Mortality Total Mortality (%) <0.61 (n=156) (n=141) (n=186) (n=310) (n=709) Risk increases with ABI values below 1.0 and above (n=1750) (n=1578) (n=696) N = (n=156) >1.40 (n=66) Baseline ABI Age range mid- to late-50s Median duration of follow-up was 11 years O Hare AM et al. Circulation. 2006;113:
31 ABI correlates with mortality ABI collaboration meta-analysis. JAMA 2008;300(2):197
32 MI Risk Increases as the ABI decreases Framingham High Risk = 20% at 10 years Every patient with PAD is at very high risk Fatal and non-fatal CV events and all cause mortality Event Outcomes per Year (%) N= 1500, cohort, Primary Care, Scotland 1.4% > <0.7 ABI PAD 10-year risk: 20% Annual risk 2% 10-year risk: 38% Annual risk 3.8% Leng GC, et al. Brit Med J. 1996;313:
33 10-Year Natural History in Patients With Intermittent Claudication Patients (%) Survival MI Intervention Amputation 6.8% annual risk of death 2.0% risk of MI 1.0% risk of intervention 0.4% risk of amputation Time (years) Ouriel K. Lancet. 2001;358;
34 6-month outcomes in critical limb ischemia Fate of Patients With CLI After Initial Treatment Summary of 6-month outcomes from 19 studies Alive with amputation 35% Dead 20% Alive without amputation 45% Critical limb ischemia: ischemic rest pain, non-healing wounds, or gangrene Dormandy JA, Rutherford RB. J Vasc Surg. 2000;31:S1-S296.
35 Glycemic control and macrovascular endpoints in DM-2 and LE-PAD Study PROactive VADT Primary Macrovascular Endpoints ACS, nonfatal MI, endovascular/ surgical revascularization on leg arteries, or Amputation MI, stroke, CVD death, CHF, PVD surgery, inoperable CAD, or Amputation Intervention or goals Pioglitazone vs placebo 1.5% Reduction in HgbA1c ø ø Outcomes Non-significant 10% reduction in macrovascular Events No significant benefit in intensive glycemic control on composite Outcome UKPDS survivor cohort Death from MI, stroke, or PVD FPG <108 mg/dl w10- y Follow-up of original trial: intensive glycemic control reduced MI but not PAD UKPDS Death from MI, stroke, or PVD FPG <108 mg/dl Nonsignificant reduction in PAD RR 0.65 (95% CI, ). ACCORD ADVANCE Nonfatal MI, nonfatal stroke, or CVD death Composite of macrovascular and microvascular events HgbA1c <6.0% HgbA1c <6.5% ø ø ø ø Increased mortality in intensive glycemic control Group No significant effect on macrovascular events; reduction in combined macrovascular and microvascular Events Tattersall MC, et al. Surg Clin North Am. 2013;93(4):761-78
36 Quitting tobacco and controlling BP and Survival in LE-PAD Smoking cessation Intensive BP management in LE-PAD patients, ABCD trial 100 Cumulative Survival (%) Australian census Tobacco abstinence Continued tobacco use Years Postoperative 133 Patients observed after bypass graft Faulkner KW, et al. Med J Aust. 1983;1: Mehler, et al. Circulation. 2003;107;
37 Intensive Antihypertensive Therapy in LE- PAD: The ABCD Trial Moderate treatment n = 227 Intensive treatment n = 227 *enalapril or nisoldipine Odds of MI, Stroke or Vascular Death Baseline ABI Mehler, et al. Circulation. 2003;107;
38 Clopidogrel vs. Aspirin in MI, Ischemic Stroke, or Vascular Death CAPRIE Cumulative Event Rate (%) 8.7%* 16 Overall Relative Risk ASA Reduction % 5.32% Clopidogrel Months of Follow-Up N=19,185 CAPRIE. Lancet. 1996;348:
39 Antiplatelet (Aspirin) use Risk of Vascular Events in High-Risk Patients: Antithrombotic Trialists Collaboration Risk category (N of trials) Patients with event (%) Risk vs control Antiplatelet Control Reduced Increased Claudication (n=26) Surgical bypass grafting (n=12) Peripheral Vascular intervention (n=4) N=9706 All LE-PAD trials (n=42) % RRR (P<.001) Antithrombotic Trialists Collaboration. Brit Med J. 2002;324:71-86.
40 Risk Reduction of Clopidogrel vs. Aspirin in Patients With PAD Aspirin favored Clopidogrel favored Stroke N=19,185 MI PAD All patients CAPRIE Steering Committee. Lancet. 1996;348:
41 CHARISMA: Clopidogrel+Aspirin vs. Aspirin Alone and MI, Stroke, or CV Death Cumulative Event Rate* (%) First occurrence of MI (fatal or nonfatal), stroke (fatal or nonfatal), or CV death Months Since Randomization Placebo + ASA 7.3% Clopidogrel + ASA 6.8% RRR 7.1% (95% CI: -4.5%, 17.5%) P=0.22 Bhatt DL, Fox KA, Hacke W, et al. N Engl J Med 2006;354:1706.
42 CHARISMA: Primary Efficacy Results (MI/Stroke/CV Death) by Pre-Specified Entry Category Population RRR (95% CI) P Qualifying CAD, CVD, or PAD 0.88 (0.77, 0.998) (n=12,153) Multiple risk factors 1.20 (0.91, 1.59) 0.20 (n=3,284) Overall population* 0.93 (0.83, 1.05) 0.22 (N=15,603) Clopidogrel better Placebo better CAD=coronary artery disease; CI=confidence interval; CVD=cardiovascular disease; MI=myocardial infarction; RRR=relative risk ratio. *A statistical test for interaction showed marginally significant heterogeneity (P=0.045) in treatment response for these prespecified subgroups of patients. Adapted from Bhatt DL, Fox KA, Hacke W, et al. N Engl J Med 2006;354:1706..
43 Cilostazol dosing and Pentoxifylline and claudication walking distance % Change From Baseline MWD (mean) Cilostazol 100 mg 2 times/day (n=227) Pentoxifylline 400 mg 3 times/day (n=232) Placebo (n=239) P<0.001 vs pentoxifylline Treatment (weeks) Randomized, Placebo Controlled Trials No. of Patients Cilostazol, 100 mg bid Pentoxifylline, 400 mg tid Cilostazol, 100 mg bid Cilostazol, 50 mg bid Cilostazol, 100 mg bid Relative Improvement vs. Placebo Dawson DL, et al. Am J Med. 2000;109: Hiatt WR. N Engl J Med. 2001;344;
44 Ramipril Walking Times and QOL Multicenter RCT N= 212 Ahimastos AA.JAMA. 2013;309(5):
45 Cilostazol mortality after PVI Fig 6 Forest plot of mortality outcomes. CI, Confidence interval; RCT, randomized controlled trial. Warner CJ, et al. J Vasc Surg 2014;59:
46 ACEI (ramipril vs. others) Δ in ABI Shahin Y, et al. Atherosclerosis 2013;231:
47 CLaudication: Exercise vs. Endoluminal Revascularization
48 Research Question To compare the relative effect of Optimal medical therapy vs. Optimal therapy + supervised exercise vs. Optimal therapy + Revascularization in the management of patients with claudication
49 Study design Multicenter (22 US sites) Randomized Open label NHLBI sponsored
50 Inclusion and Exclusion Inclusion à >2<11 minutes on Gardner treadmill protocol and hemodynamically significant aortoiliac disease (ABI <0.9, CFA-AT >140 ms, PSVR >2, CTA/MRA >60%, Angio >50%) Exclusion à CLI, comorbidities limiting ambulation
51 Treatments OPTIMAL cilostazol 100 mg bid as tolerated, written and oral advice about exercise and diet STENTING optimal plus stent revascularization of aortoiliac PAD EXERCISE optimal plus 26 weeks of supervised exercise, 3x/wk, 1 hour sessions followed by 1 year of telephone-based exercise counseling
52 Final: 79 pts 29% dropout
53
54
55 Baseline medication use No information on ACEI No information on medication use at f/u CLEVER 6 month results. Circulation. 201
56 Endpoints Primary: Peak walking time (PWT) on Gardner treadmill protocol Secondary: Claudication onset time (COT), QOL, CV disease biomarkers Interim f/u at 6 months Total planned f/u 18 months
57 Sample size Circulation. 2012;125:1
58 Analyses All 3 pairwise comparisons of change in PWT between baseline and 18 months among the 3 treatment groups à analysis of covariance (ANCOVA) adjusted for baseline PWT, baseline cilostazol use, and study region, Sequential testing was performed so as to allow a 2- sided 0.05 level of significance for each pairwise comparison.
59 CLEVER 6 moths 1 endpoint: Change in peak walking time 8 (p < 0.05 for all comparisons) 4 % QOL: highest with stenting, intermediate with supervised exercise, and lowest with optimal medical therapy alone 0 Optimal medical therapy ( N = 22) Stent revascularization (N = 46) Exercise program ( N = 43) Circulation 2012;125(
60
61 Mean peak walking time (primary endpoint)
62 Mean claudication onset time
63
64
65 Treatment delivery 91% cilostazol compliance in all groups 71% exercise compliance 100% procedure success for stenting No crossover at 6 months; 7% crossover at 18 months
66 Caveats Slow enrollment (4 yrs at 29 centers) 10:1 screening to enrollment ratio Stenting plus exercise group was dropped (these 8 patients were excluded from analyses) Patient dropout rate 20% Early termination (when 51% of original sample size had enrolled; 36% of original sample size completed 18-month f/u)
67 Conclusions CLEVER Optimal care à little benefit. Cilostazol less than expected improvement Supervised Exercise and Stenting have benefits over optimal care Exercise: better treadmill performance Stenting: better quality of life Discordant findings limit interpretation and impact in practice Potential confounders: unblinded design, dropping of 4 th exercise +stenting group, early termination. Dropout rates could have skewed the results No other clinical outcomes known (e.g., major adverse limb events, major adverse cardiac events) CLEVER à very selected cohort
ACC NY Cardiovascular Symposium
ACC NY Cardiovascular Symposium Peripheral Vascular Disease: Watch the Heart and the Brain Evolving Role of Exercise, ACE-Inhibitors, Interventional and Surgical Options Mark A. Creager, M.D President,
More informationJohn E. Campbell, MD. Assistant Professor of Surgery and Medicine Department of Vascular Surgery West Virginia University, Charleston Division
John E. Campbell, MD Assistant Professor of Surgery and Medicine Department of Vascular Surgery West Virginia University, Charleston Division John Campbell, MD For the 12 months preceding this CME activity,
More informationPeripheral Artery Disease Role of Exercise, Endovascular and Surgical Options
Peripheral Artery Disease Role of Exercise, Endovascular and Surgical Options Jeffrey W. Olin, D.O., F.A.C.C., F.A.H.A. Professor of Medicine (Cardiology) Director of Vascular Medicine & the Vascular Diagnostic
More informationMedical Therapy for Peripheral Artery Disease
Medical Therapy for Peripheral Artery Disease Beau M. Hawkins, MD, FSCAI University of Oklahoma Health Sciences Center, Oklahoma City, OK Sahil A. Parikh, MD, FSCAI Columbia University Medical Center,
More informationThe Changing Landscape of Managing Patients with PAD- Update on the Evidence and Practice of Care in Patients with Peripheral Artery Disease
Interventional Cardiology and Cath Labs The Changing Landscape of Managing Patients with PAD- Update on the Evidence and Practice of Care in Patients with Peripheral Artery Disease Manesh R. Patel MD Chief,
More informationIs there enough evidence for DAPT after endovascular intervention for PAOD?
Is there enough evidence for DAPT after endovascular intervention for PAOD? Prof. I. Baumgartner Head Clinical & Interventional Angiology University Hospital Bern Disclosure Speaker name:...i. Baumgartner...
More informationClaudication Exercise vs. Endoluminal Revascularization
Claudication Exercise vs. Endoluminal Revascularization Anthony J. Comerota, MD, FACS, FACC Director, Jobst Vascular Institute Adjunct Professor of Surgery, University of Michigan Disclosures NIH Research
More informationClaudication Treatment Comparative Effectiveness: 6 Month Outcomes from the CLEVER Study
Claudication Treatment Comparative Effectiveness: 6 Month Outcomes from the CLEVER Study Authors: Murphy TP, Cutlip DE, Regensteiner JG, Mohler ER, Cohen DC, Reynolds MR, Lewis BA, Cerezo J, Oldenburg
More informationTreatment Strategies For Patients with Peripheral Artery Disease
Treatment Strategies For Patients with Peripheral Artery Disease Presented by Schuyler Jones, MD Duke University Medical Center & Duke Clinical Research Institute AHRQ Comparative Effectiveness Review
More informationA new era in the treatment of peripheral artery disease (PAD)?
A new era in the treatment of peripheral artery disease (PAD)? Prof. Dr. Jan Beyer-Westendorf Head of Thrombosis Research, University Hospital Carl Gustav Carus, TU Dresden; Germany Senior Lecturer Thrombosis
More informationHow Do We Optimize the Medical Therapy of Patients with Critical Limb Ischemia?
How Do We Optimize the Medical Therapy of Patients with Critical Limb Ischemia? Ehrin J. Armstrong, MD MSc MAS Director, Interventional Cardiology Director, Vascular Laboratory VA Eastern Colorado Healthcare
More informationAntiplatelet Therapy in Primary CVD Prevention and Stable Coronary Artery Disease. Καρακώστας Γεώργιος Διευθυντής Καρδιολογικής Κλινικής, Γ.Ν.
Antiplatelet Therapy in Primary CVD Prevention and Stable Coronary Artery Disease Καρακώστας Γεώργιος Διευθυντής Καρδιολογικής Κλινικής, Γ.Ν.Κιλκίς Primary CVD Prevention A co-ordinated set of actions,
More informationMedical Management of Vascular Disease KEITH E SWANSON MD ND ACADEMY OF FAMILY PHYSICIANS FAMILY MEDICINE UPDATE JANUARY 2017
Medical Management of Vascular Disease KEITH E SWANSON MD ND ACADEMY OF FAMILY PHYSICIANS FAMILY MEDICINE UPDATE JANUARY 2017 Objectives 1. Appreciate the long term implications of PAD 2. Appreciate the
More informationWhat s New in the Management of Peripheral Arterial Disease
What s New in the Management of Peripheral Arterial Disease Sibu P. Saha, MD, MBA Professor of Surgery Chairman, Directors Council Gill Heart Institute University of Kentucky Lexington, KY Disclosure My
More informationEvidence-Based Optimal Treatment for SFA Disease
Evidence-Based Optimal Treatment for SFA Disease Endo first Don t burn surgical bridge Don t stent if possible Javairiah Fatima, MD Assistant Professor of Surgery Division of Vascular and Endovascular
More informationHow Long Patietns Will Be on Dual Antiplatelet Therapy?
How Long Patietns Will Be on Dual Antiplatelet Therapy? Ron Waksman,, MD, FACC Professor of Medicine (Cardiology) Georgetown University Associate Director, Division of Cardiology, Washington Hospital Center
More informationEvolving Challenges in the Evaluation and Treatment of Lower Extremity PAD -- The Peripheral Academic Research Consortium (PARC)
Evolving Challenges in the Evaluation and Treatment of Lower Extremity PAD -- The Peripheral Academic Research Consortium (PARC) W. Schuyler Jones, MD FACC Director, Adult Cardiac Catheterization Laboratory
More informationRevascularisation for Claudication: When is it indicated, when not? Markus Haumer Landesklinikum Baden-Mödling Austria
Revascularisation for Claudication: When is it indicated, when not? Markus Haumer Landesklinikum Baden-Mödling Austria Disclosure Disclosure Speaker name: Markus Haumer, MD I have the following potential
More informationPAD and CRITICAL LIMB ISCHEMIA: EVALUATION AND TREATMENT 2014
PAD and CRITICAL LIMB ISCHEMIA: EVALUATION AND TREATMENT 2014 Van Crisco, MD, FACC, FSCAI First Coast Heart and Vascular Center, PLLC Jacksonville, FL 678-313-6695 Conflict of Interest Bayer Healthcare
More information7 th Munich Vascular Conference
7 th Munich Vascular Conference Secondary prevention of major cardiovascular events in patients with CHD or PAD - What can we learn from EUCLID and COMPASS, evaluating Clopidogrel, Ticagrelor and Univ.-Prof.
More informationGuidelines for Management of Peripheral Arterial Disease
Guidelines for Management of Peripheral Arterial Disease Subhash Banerjee, MD, FACC, FSCAI Professor of Medicine, Univ. of Texas Southwestern Medical Center Chief, Division of Cardiology, VA North Texas
More informationDiagnosis and Endovascular Treatment of Critical Limb Ischemia: What You Need to Know S. Jay Mathews, MD, MS, FACC
Diagnosis and Endovascular Treatment of Critical Limb Ischemia: What You Need to Know S. Jay Mathews, MD, MS, FACC Interventional Cardiologist/Endovascular Specialist Bradenton Cardiology Center Bradenton,
More informationPeripheral Arterial Disease: Objectives. Disclosure. Definition: Peripheral Arterial Disease (PAD)
Geriatric Grand Rounds Tuesday, April 21, 2009 12:00 noon Dr. Bill Black Auditorium Glenrose Rehabilitation Hospital In keeping with Glenrose Rehabilitation Hospital policy, speakers participating in this
More informationEarly Identification of PAD: Evidence to Refute USPSTF Position on Screening
Early Identification of PAD: Evidence to Refute USPSTF Position on Screening Mehdi H. Shishehbor, DO, MPH, PhD Director Endovascular Services Interventional Cardiology & Vascular Medicine Department of
More informationSession Antiplatelet Therapy: How, Why and When? In patients with ischemic stroke/tia
GROUPE HOSPITALIER BICHAT-CLAUDE BERNARD PARIS DIDEROT UNIVERSITY - PARIS 7 Session Antiplatelet Therapy: How, Why and When? In patients with ischemic stroke/tia Pierre Amarenco INSERM U-698 and Denis
More informationIntercepting PAD. Playbook for Cardiovascular Care 2018 February 24, Jonathan D Woody, MD, FACS. University Surgical Vascular
Intercepting PAD Playbook for Cardiovascular Care 2018 February 24, 2018 Jonathan D Woody, MD, FACS University Surgical Vascular Attending Vascular Surgeon - Piedmont Athens Regional Adjunct Clinical Associate
More information03/30/2016 DISCLOSURES TO OPERATE OR NOT THAT IS THE QUESTION CAROTID INTERVENTION IS INDICATED FOR ASYMPTOMATIC CAROTID OCCLUSIVE DISEASE
CAROTID INTERVENTION IS INDICATED FOR ASYMPTOMATIC CAROTID OCCLUSIVE DISEASE Elizabeth L. Detschelt, M.D. Allegheny Health Network Vascular and Endovascular Symposium April 2, 2016 DISCLOSURES I have no
More informationTicagrelor versus Clopidogrel in Symptomatic Peripheral Artery Disease (EUCLID Trial)
Audience Interaction The chat box is available on the left hand side. Let us know who you are and where you re viewing from! Questions can be entered by hitting the green box with a question mark in it
More informationThe Case for PCI as the Preferred Therapy in Most Patients with Chronic Stable Angina
The Case for PCI as the Preferred Therapy in Most Patients with Chronic Stable Angina Ajay J. Kirtane,, MD Columbia University Medical Center The Cardiovascular Research Foundation Conflict of Interest
More informationRisk factor modification in intermittent claudication: effect on life expectancy and walking capacity
European Heart Journal Supplements (2002) 4 (Supplement B), B50 B54 Risk factor modification in intermittent claudication: effect on life expectancy and walking capacity Section of Vascular Medicine, Divisions
More informationArteriopatie periferiche. Trattamento delle arteriopatie periferiche: AVK versus Antiaggregante
Arteriopatie periferiche Trattamento delle arteriopatie periferiche: AVK versus Antiaggregante Anna Falanga USC Immunoematologia e Medicina Trasfusionale ASST Papa Giovanni XXIII, Bergamo Obiettivi della
More information3-year results of the OLIVE registry:
3-year results of the OLIVE registry: A prospective multicenter study in patients with critical limb ischemia Osamu Iida, MD Kansai Rosai Hospital Cardiovascular Center Amagasaki, Hyogo, Japan Disclosure
More informationPractical Point in Diabetic Foot Care 3-4 July 2017
Diabetic Foot Ulcer : Role of Vascular Surgeon Practical Point in Diabetic Foot Care 3-4 July 2017 Supapong Arworn, MD Division of Vascular and Endovascular Surgery Department of Surgery, Chiang Mai University
More informationEugene Barrett M.D., Ph.D. University of Virginia 6/18/2007. Diagnosis and what is it Glucose Tolerance Categories FPG
Diabetes Mellitus: Update 7 What is the unifying basis of this vascular disease? Eugene J. Barrett, MD, PhD Professor of Internal Medicine and Pediatrics Director, Diabetes Center and GCRC Health System
More informationClopidogrel has been evaluated in clinical trials that included cardiovascular patients
REVIEW ARTICLE Comparative Benefits of Clopidogrel and Aspirin in High-Risk Patient Populations Lessons From the CAPRIE and CURE Studies Jack Hirsh, CM, MD, FRCPC, FRACP, FRSC, DSc; Deepak L. Bhatt, MD,
More informationJoshua A. Beckman, MD. Brigham and Women s Hospital
Peripheral Vascular Disease: Overview, Peripheral Arterial Obstructive Disease, Carotid Artery Disease, and Renovascular Disease as a Surrogate for Coronary Artery Disease Joshua A. Beckman, MD Brigham
More information9/29/2015. Primary Prevention of Heart Disease: Objectives. Objectives. What works? What doesn t?
Primary Prevention of Heart Disease: What works? What doesn t? Samia Mora, MD, MHS Associate Professor, Harvard Medical School Associate Physician, Brigham and Women s Hospital October 2, 2015 Financial
More informationOptimal Duration and Dose of Antiplatelet Therapy after PCI
Optimal Duration and Dose of Antiplatelet Therapy after PCI Donghoon Choi, MD, PhD Severance Cardiovascular Center Yonsei University College of Medicine Optimal Duration of Antiplatelet Therapy after PCI
More informationPeripheral Arterial Disease (PAD): Presentation, Diagnosis, and Treatment
Peripheral Arterial Disease (PAD): Presentation, Diagnosis, and Treatment Prepared and Presented by Jon Manocchio, Pharm D Blanchard Valley Hospital October 2011 Introduction PAD is a condition that is
More informationPAD Characterization Within A Healthcare System" RAPID Face-to-Face Meeting Schuyler Jones, MD September 14, 2016
PAD Characterization Within A Healthcare System" RAPID Face-to-Face Meeting Schuyler, MD September 14, 2016 Interventional Cardiology and Cath Labs Disclosures Research Grants: Agency for Healthcare Research
More informationJohn E. Campbell, MD Assistant Professor of Surgery and Medicine Department of Vascular Surgery West Virginia University, Charleston Division
John E. Campbell, MD Assistant Professor of Surgery and Medicine Department of Vascular Surgery West Virginia University, Charleston Division John Campbell, MD For the 12 months preceding this CME activity,
More informationIntroduction. Risk factors of PVD 5/8/2017
PATHOPHYSIOLOGY AND CLINICAL FEATURES OF PERIPHERAL VASCULAR DISEASE Dr. Muhamad Zabidi Ahmad Radiologist and Section Chief, Radiology, Oncology and Nuclear Medicine Section, Advanced Medical and Dental
More informationThe Diabetes Link to Heart Disease
The Diabetes Link to Heart Disease Anthony Abe DeSantis, MD September 18, 2015 University of WA Division of Metabolism, Endocrinology and Nutrition Oswald Toosweet Case #1 68 yo M with T2DM Diagnosed DM
More informationThe Burden of the Diabetic Heart
The Burden of the Diabetic Heart Dr. Ghaida Kaddaha (MBBS, MRCP-UK, FRCP-london) Diabetes Unit Rashid Hospital Dubai U.A.E Risk of CVD in Diabetes Morbidity and mortality from CVD is 2-4 fold higher than
More informationBalancing Efficacy and Safety of P2Y12 Inhibitors for ACS Patients
SYP.CLO-A.16.07.01 Balancing Efficacy and Safety of P2Y12 Inhibitors for ACS Patients dr. Hariadi Hariawan, Sp.PD, Sp.JP (K) TOPICS Efficacy Safety Consideration from Currently Available Antiplatelet Agents
More informationAdults With Diagnosed Diabetes
Adults With Diagnosed Diabetes 1990 No data available Less than 4% 4%-6% Above 6% Mokdad AH, et al. Diabetes Care. 2000;23(9):1278-1283. Adults With Diagnosed Diabetes 2000 4%-6% Above 6% Mokdad AH, et
More informationESC GUIDELINES ON DIABETES AND CARDIOVASCULAR DISEASES
ESC GUIDELINES ON DIABETES AND CARDIOVASCULAR DISEASES Pr. Michel KOMAJDA Institute of Cardiology - IHU ICAN Pitie Salpetriere Hospital - University Pierre and Marie Curie, Paris (France) DEFINITION A
More informationOptimal medical therapy in patients with stable CAD
Optimal medical therapy in patients with stable CAD Robert Storey Professor of Cardiology, University of Sheffield and Academic Director and Honorary Consultant Cardiologist, Cardiology and Cardiothoracic
More informationRole of Clopidogrel in Acute Coronary Syndromes. Hossam Kandil,, MD. Professor of Cardiology Cairo University
Role of Clopidogrel in Acute Coronary Syndromes Hossam Kandil,, MD Professor of Cardiology Cairo University ACS Treatment Strategies Reperfusion/Revascularization Therapy Thrombolysis PCI (with/ without
More informationΑντιθρομβωτική αγωγή σε ασθενείς με περιφερική αρτηριακή νόσο των κάτω άκρων
Αντιθρομβωτική αγωγή σε ασθενείς με περιφερική αρτηριακή νόσο των κάτω άκρων Μ. Ματσάγκας, MD, PhD, FEBVS Καθηγητής Αγγειοχειρουργικής Πανεπιστήμιο Θεσσαλίας Prevalence (millions) PAD Affects Millions
More informationDapagliflozin and Outcomes in Patients with Peripheral Artery Disease: Insights from DECLARE-TIMI 58
Dapagliflozin and Outcomes in Patients with Peripheral Artery Disease: Insights from DECLARE-TIMI 58 Marc P. Bonaca MD MPH for the DECLARE TIMI 58 Investigators American College of Cardiology March 2019
More informationDisclosures. TASC, AHA, SVS: What s Happening with the Guidelines? How Are They Relevant? Purpose of Practice Guidelines
TASC, AHA, SVS: What s Happening with the Guidelines? How Are They Relevant? Michael S. Conte MD, FACS Division of Vascular and Endovascular Surgery Co-Director, Heart and Vascular Center UCSF Medical
More informationInterventional Treatment First for CLI
Interventional Treatment First for CLI Patrick Alexander, MD, FACC, FSCAI Interventional Cardiology Medical Director, Critical Limb Clinic Providence Heart Institute, Southfield MI 48075 Disclosures Consultant
More informationMaximally Invasive Vascular Surgery for the Treatment of Critical Limb Ischemia
Maximally Invasive Vascular Surgery for the Treatment of Critical Limb Ischemia Traci A. Kimball, MD Department of Surgery Grand Rounds Septemember 13, 2010 Overview Defining Critical Limb Ischemia Epidemiology
More informationAmputation as a Last Resort A Multidisciplinary Approach to Limb Salvage
Amputation as a Last Resort A Multidisciplinary Approach to Limb Salvage George L. Adams, MD, MHS, MBA, FACC, FSCAI Clinical Associate Professor of Medicine University of North Carolina Health System Director
More informationThe Clinical Unmet need in the patient with Diabetes and ACS
The Clinical Unmet need in the patient with Diabetes and ACS Professor Kausik Ray (UK) BSc(hons), MBChB, MD, MPhil, FRCP (lon), FRCP (ed), FACC, FESC, FAHA Diabetes is a global public health challenge
More informationRegulatory Hurdles for Drug Approvals
Regulatory Hurdles for Drug Approvals William R. Hiatt, MD Professor of Medicine/Cardiology University of Colorado School of Medicine President, CPC Clinical Research 25 min Conflicts CPC Clinical Research
More informationVascular Protection in Patients with CAD and PAD: New Options
Vascular Protection in Patients with CAD and PAD: New Options Professor Dr Eike Sebastian Debus Direktor Klinik für Gefäßmedizin Gefäßchirurgie Angiologie Interventionelle Therapie Deutsches Aortenzentrum
More informationRegistry Assessment of Peripheral Interventional Devices (RAPID)
Registry Assessment of Peripheral Interventional Devices (RAPID) Adding Data Sources May 2, 2018 W. Schuyler Jones, MD Duke Clinical Research Institute Duke Heart Center Disclosures Research Grants: Agency
More informationAntihypertensive Trial Design ALLHAT
1 U.S. Department of Health and Human Services Major Outcomes in High Risk Hypertensive Patients Randomized to Angiotensin-Converting Enzyme Inhibitor or Calcium Channel Blocker vs Diuretic National Institutes
More informationEffective Health Care Program
Comparative Effectiveness Review Number 118 Effective Health Care Program Treatment Strategies for Patients With Peripheral Artery Disease Executive Summary Background Peripheral artery disease (PAD) refers
More informationProf. Jindřich Špinar, MD
Prof. Jindřich Špinar, MD Head of the Internal Cardiology dpt., University Hospital Brno Focuses on clinical cardiology, acute and chronic heart failure, ischemic heart gisease, hypertension Vice head
More informationMost Important Clinical Trials of the Past Decade in Vascular Intervention
Most Important Clinical Trials of the Past Decade in Vascular Intervention Andrew J. P. Klein, MD, FACC, FSCAI Interventional Cardiology Vascular and Endovascular Medicine Piedmont Heart Institute Atlanta,
More informationDisclosures. Theodore A. Bass MD, FSCAI. The following relationships exist related to this presentation. None
SCAI Fellows Course December 10, 2013 Disclosures Theodore A. Bass MD, FSCAI The following relationships exist related to this presentation None Current Controversies on DAPT in PCI Which drug? When to
More informationClinical and Economic Value of Rivaroxaban in Coronary Artery Disease
CHRISTOPHER B. GRANGER, MD Professor of Medicine Division of Cardiology, Department of Medicine; Director, Cardiac Care Unit Duke University Medical Center, Durham, NC Clinical and Economic Value of Rivaroxaban
More informationSTATINS FOR PAD Long - term prognosis
STATINS FOR PAD Long - term prognosis Prof. Pavel Poredos, MD, PhD Department of Vascular Disease University Medical Centre Ljubljana Slovenia DECLARATION OF CONFLICT OF INTEREST No conflict of interest
More informationAre DES and DEB worth the cost in BTK interventions?
Are DES and DEB worth the cost in BTK interventions? Thomas Zeller, MD University Heart-Center Freiburg-Bad Krozingen Bad Krozingen, Germany -1- My Disclosures: Advisory Board: Medtronic-Invatec, Gore,
More informationCarotid Artery Stenosis
Evidence-Based Approach to Carotid Artery Stenosis Seong-Wook Park, MD Division of Cardiology, Asan Medical Center University of Ulsan College of Medicine, Seoul, Korea Carotid Artery Stenosis Carotid
More informationCardiovascular Disease in CLI Patients
L E I P Z I G I N T E R V E N T I O N A L C O U R S E 2 0 1 8 Nurse and Technician Forum - Part II Cardiovascular Disease in CLI Patients Corneliu Popescu Universitätsklinikum Leipzig Disclosure Speaker
More informationCath Lab Essentials : Peripheral Vascular Disease in Patients with CAD
Cath Lab Essentials : Peripheral Vascular Disease in Patients with CAD Pranav M. Patel, MD, FACC, FSCAI Interim Chief & Associate Professor of Medicine Director, Cardiac Catheterization Lab University
More informationCoronary Artery Disease in 2015: Acute Coronary Syndrome and beyond (Primary and Secondary Prevention of CAD)
Coronary Artery Disease in 2015: Acute Coronary Syndrome and beyond (Primary and Secondary Prevention of CAD) Andrew R. Waxler, MD, FACC Berks Cardiologists, Ltd. President Elect, Berks County Medical
More informationLarry Diaz, MD, FSCAI Mehdi H. Shishehbor, DO, FSCAI
PAD Diagnosis Larry Diaz, MD, FSCAI Metro Health / University of Michigan Health, Wyoming, MI Mehdi H. Shishehbor, DO, FSCAI University Hospitals Harrington Heart & Vascular Institute, Cleveland, OH PAD:
More informationAspirine pour tous les patients à haut risque?
Aspirine pour tous les patients à haut risque? Gilles Lemesle, Centre Hémodynamique, CHRU de Lille Cliquez pour modifier le style des sous titres du masque The clinical point of view Ratio Ischaemic events
More informationHow to Choose Between Carotid Stenting and Carotid Endarterectomy for Stroke Prevention
How to Choose Between Carotid Stenting and Carotid Endarterectomy for Stroke Prevention Christopher J. White MD, MSCAI Chief of Medical Services, Professor and Chairman of Medicine Ochsner Medical Center
More informationIntroduction to Peripheral Arterial Disease. Stacey Clegg, MD Interventional Cardiology August
Introduction to Peripheral Arterial Disease Stacey Clegg, MD Interventional Cardiology August 20 2014 Outline (and for the ABIM board exam * ** ***) Prevalence* Definitions Lower Extremity: Aorta*** Claudication***
More informationMacrovascular Disease in Diabetes
Macrovascular Disease in Diabetes William R. Hiatt, MD Professor of Medicine/Cardiology University of Colorado School of Medicine President, CPC Clinical Research Conflicts CPC Clinical Research (University-based
More informationAnti-platelet therapies and dual inhibition in practice
Anti-platelet therapies and dual inhibition in practice Therapeutics; Sept. 25 th 2007 Craig Williams, Pharm.D. Associate Professor of Pharmacy Objectives 1. Understand the pharmacology of thienopyridine
More informationSESSION 3 11 AM 12:30 PM
SESSION 3 11 AM 12:30 PM for the Primary Prevention of Cardiovascular Disease: A Personalized Approach SPEAKER Samia Mora MD, MHS Presenter Disclosure Information The following relationships exist related
More informationCORONARY AND PERIPHERAL ARTERY ATHEROSCLEROSIS: WHAT CHOICE FOR ANTIPLATELET THERAPY
02_02 03/02/17 14.04 Pagina 9 CORONARY AND PERIPHERAL ARTERY ATHEROSCLEROSIS: WHAT CHOICE FOR ANTIPLATELET THERAPY P. Gresele Department of Medicine, Division of Internal and Cardiovascular Medicine, University
More informationWPCCS May2013. Mr Ian Williams Consultant Vascular Surgeon UHW. Consultant Cardiologist UHW
Peripheral Vascular Disease WPCCS May2013 Mr Ian Williams Consultant Vascular Surgeon UHW Prof Julian Halcox Prof Julian Halcox Consultant Cardiologist UHW Case 1? Ischaemic Legs History 85 years lady?varicose
More informationCase Study: Chris Arden. Peripheral Arterial Disease
Case Study: Chris Arden Peripheral Arterial Disease Patient Presentation Diane is a 65-year-old retired school teacher She complains of left calf pain when walking 50 metres; the pain goes away after she
More informationComparison Of Primary Long Stenting Versus Primary Short Stenting For Long Femoropopliteal Artery Disease (PARADE)
Comparison Of Primary Long Stenting Versus Primary Short Stenting For Long Femoropopliteal Artery Disease (PARADE) Young-Guk Ko, M.D. Severance Cardiovascular Hospital, Yonsei University Health System,
More informationIs Lower Better for LDL or is there a Sweet Spot
Is Lower Better for LDL or is there a Sweet Spot ALAN S BROWN MD, FACC FNLA FAHA FASPC DIRECTOR, DIVISION OF CARDIOLOGY ADVOCATE LUTHERAN GENERAL HOSPITAL, PARK RIDGE, ILLINOIS DIRECTOR OF CARDIOLOGY,
More informationLower Extremity Peripheral Arterial Disease: Less is Sometimes More. Spence M Taylor, M.D.
Lower Extremity Peripheral Arterial Disease: Less is Sometimes More Spence M Taylor, M.D. President, Greenville Health System Clinical University Senior Associate Dean for Academic Affairs and Diversity
More information5/2/2016. Outpatient Stroke Management Sheila Smith MD May 5, 2016
Outpatient Stroke Management Sheila Smith MD May 5, 2016 1 Management of Outpatient Stroke Objectives Review blood pressure management post stroke Review antithrombotic therapy Review statin therapy Discuss
More information2/17/2010. Grace Lin, MD Assistant Professor of Medicine University of California, San Francisco
Modern Management of Patients with Stable Coronary Artery Disease Grace Lin, MD Assistant Professor of Medicine University of California, San Francisco Scope of the Problem Prevalence of CAD: 17.6 million
More informationHyperlipidemia: Lowering the Bar on the Lipid Limbo. Community Faculty Development Symposium March 13, 2004 Hugh Huizenga MD, MPH
Mark slides Hyperlipidemia: Lowering the Bar on the Lipid Limbo Community Faculty Development Symposium March 13, 2004 Hugh Huizenga MD, MPH Hyperlipidemia is a common problem Nearly 50% of men in the
More informationUpdate on CVD and Microvascular Complications in T2D
Update on CVD and Microvascular Complications in T2D Jay S. Skyler, MD, MACP Division of Endocrinology, Diabetes, and Metabolism and Diabetes Research Institute University of Miami Miller School of Medicine
More informationWhat have We Learned in Dyslipidemia Management Since the Publication of the 2013 ACC/AHA Guideline?
What have We Learned in Dyslipidemia Management Since the Publication of the 2013 ACC/AHA Guideline? Salim S. Virani, MD, PhD, FACC, FAHA Associate Professor, Section of Cardiovascular Research Baylor
More informationDCB in my practice: How the evidence influences my strategy. Yang-Jin Park
DCB in my practice: How the evidence influences my strategy Yang-Jin Park Associate Professor Division of Vascular Surgery, Department of Surgery Samsung Medical Center Sungkyunkwan University School of
More informationDIABETES AND METABOLIC SYNDROME
TRIALS NUMBER OF PARTICIPANTS NUMBER OF WOMEN PERCENTAGE OF WOMEN MEAN AGE MEAN - (YEARS) TRIALS WITH ANALYSIS BY GENDER N, (%) 48,508 20,091 41.4% 61.1 4.3 4/7 (57.1%) HR PROactive (Dormandy et al 61
More informationCase Discussion. Disclosures. Critical Limb Ischemia: A Selective Approach to Revascularization Works Best 4/28/2012. None. 58 yo M, DM, CAD, HTN
Critical Limb Ischemia: A Selective Approach to Revascularization Works Best None Disclosures Michael S. Conte MD, FACS Division of Vascular and Endovascular Surgery Co-Director, Heart and Vascular Center
More informationAntiplatelet therapy for peripheral artery disease
Review Article Antiplatelet therapy for peripheral artery disease Rosetta Melfi, Elisabetta Ricottini Unit of Cardiovascular Sciences, Department of Medicine, Campus Bio-Medico University of Rome, Rome,
More informationPeripheral Artery Disease Compendium
Peripheral Artery Disease Compendium Circulation Research Compendium on Peripheral Artery Disease Epidemiology of Peripheral Artery Disease Pathogenesis of the Limb Manifestations and Exercise Limitations
More informationSESSION 5 2:20 3:35 PM
SESSION 5 2:20 3:35 PM for the Primary Prevention of Cardiovascular Disease: A Personalized Approach SPEAKER Samia Mora MD, MHS Presenter Disclosure Information The following relationships exist related
More informationLa terapia antiaggregante nel paziente con stroke
La terapia antiaggregante nel paziente con stroke Paolo Gresele Dipartimento di Medicina, Sez. Medicina Interna e Cardiovascolare Università di Perugia XXVII Congresso Nazionale FCSA Milano, 20-22 Ottobre
More informationThe present status of selfexpanding. for CLI: Why and when to use. Sean P Lyden MD Cleveland Clinic Cleveland, Ohio
The present status of selfexpanding and balloonexpandable tibial BMS and DES for CLI: Why and when to use Sean P Lyden MD Cleveland Clinic Cleveland, Ohio Disclosure Speaker name: Sean Lyden, MD I have
More informationSurveying the Landscape of Oral Antiplatelet Therapy in Acute Coronary Syndrome Management
Surveying the Landscape of Oral Antiplatelet Therapy in Acute Coronary Syndrome Management Jeffrey S Berger, MD, MS Assistant Professor of Medicine and Surgery Director of Cardiovascular Thrombosis Disclosures
More informationCurrent Vascular and Endovascular Management in Diabetic Vasculopathy
Current Vascular and Endovascular Management in Diabetic Vasculopathy Yang-Jin Park Associate professor Vascular Surgery, Samsung Medical Center Sungkyunkwan University School of Medicine Peripheral artery
More informationIMPORTANT INFORMATION: These materials are intended to describe common clinical considerations and procedural steps for the on-label use of
IMPORTANT INFORMATION: These materials are intended to describe common clinical considerations and procedural steps for the on-label use of referenced technologies as well as current standards of care
More information